MAPK
As MAPKs são uma família de proteínas quinases envolvidas em uma variedade de processos celulares, incluindo crescimento, proliferação, diferenciação e respostas ao estresse. A via de sinalização MAPK consiste em várias camadas, incluindo ERK, JNK e p38 MAPKs, cada uma desempenhando papéis distintos na função celular. A desregulação da sinalização MAPK está ligada ao câncer, doenças inflamatórias e distúrbios metabólicos. Na CymitQuimica, oferecemos uma ampla gama de inibidores e ativadores de MAPK para apoiar sua pesquisa em biologia celular, transdução de sinais e mecanismos de doenças.
Foram encontrados 886 produtos de "MAPK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
CC-90003
CAS:<p>CC-90003 is a selective inhibitor of ERK 1/2. It has antitumor activity.</p>Fórmula:C22H21F3N6O2Pureza:99.42%Cor e Forma:SolidPeso molecular:458.44ERK5-IN-5
CAS:<p>ERK5-IN-5 is extracellular signal-regulated kinase 5 (ERK5) inhibitor with anticancer activity anticonvulsant activity inhibits A549 cell proliferation.</p>Fórmula:C19H16ClN3OPureza:99.77%Cor e Forma:SoildPeso molecular:337.8LUT014
CAS:<p>LUT014 is a B-Raf inhibitor (IC50: 11.7 nM) and developed to decrease dose-limiting acneiform lesions associated with EGFR Inhibitors treatment.</p>Fórmula:C27H19F3N8OPureza:99.03%Cor e Forma:SolidPeso molecular:528.49MAP4K4-IN-3
CAS:<p>MAP4K4-IN-3 (Compound 17) may be a viable target for antidiabetic agents, a serine/threonine protein kinase.</p>Fórmula:C15H12ClN5Pureza:98.07%Cor e Forma:SolidPeso molecular:297.74Pepinh-TRIF TFA
<p>Pepinh-TRIF TFA is a 30 aa peptide associated with the immune system that blocks TRIF signaling by interfering with TLR-TRIF interaction (TLR-TRIF interaction</p>Fórmula:C180H279F3N58O40S2Pureza:98%Cor e Forma:SolidPeso molecular:4014.09741ERK5-IN-6
CAS:<p>ERK5-IN-6 is an ERK5 kinase inhibitor with antiproliferative, anticonvulsant, and antitumor activity for the study of central nervous system related diseases.</p>Fórmula:C23H21N3Pureza:98.59%Cor e Forma:SoildPeso molecular:339.43B-Raf IN 2
CAS:<p>B-Raf IN 2, compound Ia, is a highly effective and specific inhibitor of BRAF. It exhibits significant potential for cancer research.</p>Fórmula:C20H17F2N5O4SPureza:98.86%Cor e Forma:SolidPeso molecular:461.44MRTX-1257
CAS:<p>MRTX-1257: selective, irreversible KRAS G12C inhibitor; IC50 of 900 pM; 31% bioavailable in mice; 77% target engagement.</p>Fórmula:C33H39N7O2Pureza:97.3% - 99.07%Cor e Forma:SolidPeso molecular:565.71AX-15836
CAS:<p>AX-15836 is an inhibitor of ERK5 (IC50 : 8 nM).</p>Fórmula:C32H40N8O5SPureza:98.96%Cor e Forma:SolidPeso molecular:648.78MRTX0902
CAS:<p>MRTX0902 is an effective and high selective inhibitor of SOS1 with an IC50 of 46 nM and a Ki of 2 nM.</p>Fórmula:C22H24N6OPureza:99.69%Cor e Forma:SolidPeso molecular:388.47ACBI3
CAS:<p>ACBI3 is a selective pan-KRAS degrader with anticancer activity that degrades oncogenic KRAS. ACBI3 inhibits the growth of most cancer cell lines driven by KRAS mutations.</p>Fórmula:C50H62N14O6S2Pureza:99.24%Cor e Forma:SolidPeso molecular:1019.25HI-TOPK-032
CAS:<p>HI-TOPK-032 is an effective and specific inhibitor of TOPK.</p>Fórmula:C20H11N5OSPureza:98.52%Cor e Forma:SolidPeso molecular:369.4GW806742X
CAS:<p>GW806742X inhibits MLKL with Kd 9.3 μM, preventing necroptosis; also targets VEGFR2.</p>Fórmula:C25H22F3N7O4SPureza:98.3%Cor e Forma:SolidPeso molecular:573.55JNK-IN-13
CAS:<p>JNK-IN-13 is a JNK inhibitor that inhibits JNK3 and JNK2 and can be used in the study of diabetes, inflammation, and neurological disorders.</p>Fórmula:C13H7ClN4SPureza:98.74%Cor e Forma:SolidPeso molecular:286.74(R)-Ketorolac
CAS:<p>(R)-Ketorolac ((+)-Ketorolac) is the R-enantiomer of Ketorolac, with potent analgesic activity.</p>Fórmula:C15H13NO3Pureza:99.55%Cor e Forma:SolidPeso molecular:255.27Cephradine
CAS:<p>Cephradine (Anspor) is a beta-lactam, first-generation cephalosporin antibiotic with bactericidal activity.</p>Fórmula:C16H19N3O4SPureza:99.63%Cor e Forma:White Crystalline Powder; Polymorphic SolidPeso molecular:349.40BI-3406
CAS:<p>BI-3406 is an orally active, highly potent and selective between KRAS and Son of Sevenless 1 (SOS1) interaction inhibitor(IC50 : 6 nM),with anticancer activity.</p>Fórmula:C23H25F3N4O3Pureza:99.2% - 99.66%Cor e Forma:SolidPeso molecular:462.46ETC-206
CAS:<p>ETC-206 is a selective inhibitor of MNK1 and MNK2 (IC50s: 64 nM and 86 nM).</p>Fórmula:C25H20N4O2Pureza:99.72% - 99.79%Cor e Forma:SolidPeso molecular:408.45Xl-281
CAS:<p>XL-281: potent oral RAF kinase inhibitor, effective on wild-type and mutants, reduces tumor growth and cell proliferation, increases apoptosis.</p>Fórmula:C24H19ClN4O4Pureza:95.77% - 98.83%Cor e Forma:SolidPeso molecular:462.89MK2-IN-3 hydrate
CAS:<p>MK2-IN-3 hydrate (MK-2 Inhibitor III) is an orally active, selective, and ATP-competitive inhibitor of MAPKAP-K2 (MK-2) (IC50 of 0.85 nM)</p>Fórmula:C21H18N4O2Pureza:99.58%Cor e Forma:SolidPeso molecular:358.39KRAS G12C inhibitor 19
CAS:<p>KRAS G12C inhibitor 19 is a potent KRAS G12C inhibitor that shows anti-tumor activity in cellular assays, and the family inhibits tumor growth.</p>Fórmula:C25H19ClF2N4O3SPureza:97.46%Cor e Forma:SolidPeso molecular:528.96PF-3644022
CAS:<p>PF-3644022 is a selective MK2 inhibitor, effective against TNFα (IC50: 5.2 nM, Ki: 3 nM), with anti-inflammatory properties. Also blocks MK3 and PRAK.</p>Fórmula:C21H18N4OSPureza:98.13%Cor e Forma:SolidPeso molecular:374.46Methylthiouracil
CAS:<p>Methylthiouracil (NSC-193526) is a thiourea antithyroid agent that inhibits the synthesis of thyroid hormone, and it is used to treat hyperthyroidism.</p>Fórmula:C5H6N2OSPureza:99.89% - >99.99%Cor e Forma:Crystals Saturated Aqueous Solution Is Neutral Or Slightly Acidic (Ntp 1992)Peso molecular:142.18INH154
CAS:<p>INH154 is a potent Nek2 and Hec1 binding (INH) inhibitor with IC50s of 120 nM in MB468 cells and 200 nM in Hela cells for INH.</p>Fórmula:C22H24N4OSPureza:99.95%Cor e Forma:SolidPeso molecular:392.52Tanzisertib
CAS:<p>Tanzisertib (CC-930) (CC-930) is a potent inhibitor of JNK1/2/3 with IC50s of 61/7/6 nM, respectively, with potential antifibrotic activity.</p>Fórmula:C21H23F3N6O2Pureza:98.66% - 99.28%Cor e Forma:SolidPeso molecular:448.44Azelnidipine
CAS:<p>Azelnidipine (UR-12592) is a dihydropyridine used as calcium channel blocker.</p>Fórmula:C33H34N4O6Pureza:99.78%Cor e Forma:Light Yellowish PowderPeso molecular:582.65SU3327
CAS:<p>SU3327 (halicin) is a potent, selective and substrate-competitive inhibitor of JNK(IC50 of 0.7 μM).</p>Fórmula:C5H3N5O2S3Pureza:98.39%Cor e Forma:SolidPeso molecular:261.3K-Ras G12C-IN-4
CAS:<p>K-Ras G12C-IN-4 是一种 KRAS G12C 共价抑制剂。</p>Fórmula:C31H33ClN4O4Pureza:99.00%Cor e Forma:SolidPeso molecular:561.07ARS-1630
CAS:<p>ARS-1630 is a mutant K-ras G12C inhibitor. It is a less active enantiomer of ARS-1620.</p>Fórmula:C21H17ClF2N4O2Pureza:97.78%Cor e Forma:SolidPeso molecular:430.84Divarasib
CAS:<p>Divarasib (GDC-6036), an investigational KRAS G12C inhibitor for solid tumors, has an IC50 of <0.01 μM.</p>Fórmula:C29H32ClF4N7O2Pureza:99.237% - 99.83%Cor e Forma:SolidPeso molecular:622.06RMC-6236
CAS:<p>RMC-6236 is a potent RAS(ON)MULTI inhibitor with broad-spectrum inhibitory activity against RAS-GTP.Cost-effective and quality-assured.</p>Fórmula:C44H58N8O5SPureza:98.24% - 99.92%Cor e Forma:SolidPeso molecular:811.05Regorafénib N-oxyde (M2)
CAS:<p>Regorafénib N-oxyde M2 is an active metabolite of Regorafenib.</p>Fórmula:C21H15ClF4N4O4Pureza:98.03% - 98.26%Cor e Forma:SolidPeso molecular:498.81Dilmapimod
CAS:<p>Dilmapimod (SB-681323) is a potent inhibitor of p38 MAPK ,it potentially suppresses inflammation in chronic obstructive pulmonary disease.</p>Fórmula:C23H19F3N4O3Pureza:97.53%Cor e Forma:SolidPeso molecular:456.42MRTF-A-IN-1
<p>MRTF-A-IN-1 (compound 14) is an inhibitor of MRTF-A. It effectively suppresses cell proliferation and induces senescence in HCC cells.</p>Fórmula:C22H21N3Cor e Forma:SolidPeso molecular:327.42Debromohymenialdisine
CAS:<p>Debromohymenialdisine is a natural product for research related to life sciences. The catalog number is T35596 and the CAS number is 75593-17-8.</p>Fórmula:C11H11N5O2Cor e Forma:SolidPeso molecular:245.242ERK1/2 inhibitor 3
CAS:<p>ERK1/2 inhibitor 3, a strong ERK1/2 blocker, may aid in cancer and inflammation research.</p>Fórmula:C28H31ClFN5O6SCor e Forma:SolidPeso molecular:620.09JIP-1(153-163)
CAS:<p>Peptide based on JIP-1(153-163) inhibits JNK with micromolar affinity; barely affects p38, ERK.</p>Fórmula:C61H104N20O14Pureza:98%Cor e Forma:SolidPeso molecular:1341.6PROTAC KRAS G12C degrader-1
<p>PROTAC KRAS G12C degrader-1, a cereblon-based degrader, promotes CRBN/KRAS G12C dimerization and facilitates the degradation of GFP-KRAS G12C in reporter cells</p>Fórmula:C50H54ClFN8O6Pureza:98%Cor e Forma:SolidPeso molecular:917.47NK7-902
<p>NK7-902 is a CRBN molecular glue degrader of NEK7. It fully degrades NEK7 in human primary monocytes and whole blood, yet only partially inhibits NLRP3-dependent IL-1β production. NK7-902 results in profound and lasting degradation of NEK7, but only temporarily blocks NLRP3 inflammasome activation in non-human primates via oral administration. The compound demonstrates activity in mouse systems.</p>Cor e Forma:Odour SolidRapaprutug
CAS:<p>Rapaprutug is a monoclonal antibody that targets human KARS1 (lysyl-tRNA synthetase 1). It can block inflammation-related signaling pathways involving KARS1, thereby reducing the production and release of inflammatory factors. Rapaprutug shows potential for research into inflammatory diseases.</p>Cor e Forma:LiquidCC-401
CAS:<p>CC-401 is a specific inhibitor of JNK (Ki: 25-50nM).</p>Fórmula:C22H24N6OPureza:98%Cor e Forma:SolidPeso molecular:388.47MC 976
CAS:<p>MC 976 is a derivative of Vitamin D3.</p>Fórmula:C27H42O3Pureza:98%Cor e Forma:SolidPeso molecular:414.63PROTAC SOS1 degrader-1
CAS:<p>PROTAC SOS1 degrader-1: potent, DC50 98.4 nM, inhibits KRAS mutant cancer cells, low-toxic antitumor.</p>Fórmula:C57H76O4ClFN10SCor e Forma:SoildPeso molecular:1050.54443R18
CAS:<p>14.3.3 protein antagonist, blocks binding to Raf-1/Bad/ASK1/exoenzyme S, competitive, no phosphorylation needed, KD ~80 nM.</p>Fórmula:C101H157N27O29S3Pureza:98%Cor e Forma:SolidPeso molecular:2309.69Rineterkib hydrochloride
CAS:<p>Rineterkib hydrochloride (B) is an oral RAF/ERK1/2 inhibitor for MAPK-driven cancers, including KRAS/BRAF-mutant NSCLC and CRC.</p>Fórmula:C26H28BrClF3N5O2Cor e Forma:SolidPeso molecular:614.89LC 2 Epimer
CAS:<p>Negative control for LC 2.</p>Fórmula:C59H71ClFN11O7SCor e Forma:SolidPeso molecular:1132.8Pan-RAS-IN-7
CAS:<p>Pan-RAS-IN-7 (Compound D101) is a broad-spectrum RAS inhibitor used in the synthesis of antibody-drug conjugates (ADCs). It is also applicable in cancer research.</p>Fórmula:C59H76N8O8Cor e Forma:SolidPeso molecular:1025.28Rutamycin
CAS:<p>Rutamycin: a macrolide antibiotic from Streptomyces rutgersensis; blocks ATPases, uncouples oxidative phosphorylation.</p>Fórmula:C44H72O11Pureza:98%Cor e Forma:SolidPeso molecular:777.049DS03090629
<p>DS03090629, an orally active MEK inhibitor, functions by competitively inhibiting MEK activity in the presence of ATP. This compound demonstrates strong binding affinity to both MEK and phosphorylated MEK, with dissociation constants (Kd) of 0.11 and 0.15 nM, respectively. It has shown efficacy in suppressing the proliferation of melanoma cell lines that overexpress BRAF mutations, achieving IC50 values of 74.3 and 97.8 nM for BRAF V600E and MEK1 F53L transfected A375 cells, respectively. DS03090629 is thus considered promising for anti-melanoma therapies.</p>Fórmula:C25H26ClN5O2Cor e Forma:SolidPeso molecular:463.96HSND80
<p>HSND80 (Compound 1) is an orally active MNK/p70S6K inhibitor, exhibiting a Kd value of 44 nM for MNK1 and 4 nM for MNK2. The residence time of HSND80 on MNK1 and MNK2 is 45 minutes and 58 minutes, respectively. HSND80 effectively inhibits non-small cell lung cancer (NSCLC) both in vitro and in vivo, and suppresses the growth of triple-negative breast cancer (TNBC) cells in vitro.</p>Cor e Forma:Odour SolidAnti-inflammatory agent 31
<p>Andrographolide derivative 31 is an anti-inflammatory that blocks NF-κB, PI3K/Akt, and ERK1/2 MAPK, and restores GSH levels to protect the liver.</p>Fórmula:C19H30O3Cor e Forma:SolidPeso molecular:306.44MEK/RAF-IN-1
<p>MEK/RAF-IN-1 (Compound 16b) serves as an inhibitor targeting both MEK and RAF, demonstrating potent efficacy with IC 50 values reported at 28 nM for MEK1, and 3 nM for both BRAF and BRAFV600E. This compound exhibits significant antitumor capabilities, effectively curbing cell proliferation in vitro in MIA PaCa-2 (G12C KRAS), HCT116 (G13D KRAS), and C26 (G12D KRAS) cells. Furthermore, MEK/RAF-IN-1 significantly restricts tumor growth in xenograft mouse models employed in the study of colorectal cancer.</p>Fórmula:C28H29F3N6O5SCor e Forma:SolidPeso molecular:618.63Vacquinol-1
CAS:<p>Vacquinol-1 is an MKK4 activator, which rapidly and selectively induces glioma cell death.</p>Fórmula:C21H21ClN2OPureza:98.67%Cor e Forma:SolidPeso molecular:352.86RM-018
CAS:<p>RM-018 inhibits active KRAS G12C & G12C/Y96D, possibly beating resistance with unique traits.</p>Fórmula:C56H72N8O8Cor e Forma:SolidPeso molecular:985.24PROTAC K-Ras Degrader-2
CAS:<p>PROTAC K-Ras degrader-2 (compound 48) is a broad-spectrum KRAS mutant PROTAC degrader that demonstrates an IC50 of ≤200 nM for KRAS G12V/RAF1. Additionally, PROTAC K-Ras degrader-2 achieves a DC50 of ≤200 nM in degrading SW620 KRAS G12D and inhibits the growth of SW620 3D cells with an IC50 of ≤20 nM.</p>Fórmula:C52H60F4N8O5Cor e Forma:SolidPeso molecular:953.077JNK3 inhibitor-8
<p>JNK3 inhibitor-8: potent, selective, oral, BBB-penetrating, IC50: JNK3=21 nM, JNK2=2203 nM, JNK1>10,000 nM; potential in Alzheimer's research.</p>Fórmula:C32H30FN7O3Cor e Forma:SolidPeso molecular:579.62KRAS inhibitor-38
CAS:<p>KRAS Inhibitor-38 (Example 18) is a potent inhibitor capable of effectively suppressing the activity of KRAS G12C, KRAS G12D, and KRAS G12V in vivo.</p>Fórmula:C53H68ClF2N9O8SCor e Forma:SolidPeso molecular:1064.68Mitogen-activated protein kinase 1
CAS:<p>Mitogen-activated protein kinase 1 (MAPK1) activates the p38/NF-κB pathway and regulates cellular processes in sepsis-associated diseases.</p>Pureza:98%Cor e Forma:SolidRac1 Inhibitor W56
CAS:<p>Peptide (45-60) blocks Rac1 binding with TrioN, GEF-H1, Tiam1 GEFs.</p>Fórmula:C74H117N19O23SPureza:98%Cor e Forma:SolidPeso molecular:1671.93SOS1-IN-18
<p>SOS1-IN-18 (Compound 8) is an inhibitor of the Son of Sevenless 1 protein (SOS1) with a dissociation constant (KD) of 2.6 nM. It disrupts the SOS1-KRAS G12C interaction with an IC50 of 3.4 nM, inhibits ERK phosphorylation in H358 cells with an IC50 of 31 nM, and curtails the proliferation of H358 cells with an IC50 of 5 nM.</p>Fórmula:C26H29F3N4O2Cor e Forma:SolidPeso molecular:486.53NecroX-2
CAS:<p>NecroX-2 is a cell-permeable necrosis inhibitor with antioxidant properties. NecroX-2 selectively suppresses necrotic cell death triggered by oxidative stress. NecroX-2 does not confer protection against apoptosis induced by staurosporine or etoposide but shows protective effects under conditions such as cold shock, hypoxia, and oxidative stress in vitro.</p>Fórmula:C25H32N4O4S2Pureza:97.12%Cor e Forma:SolidPeso molecular:516.68S6 Kinase Substrate Peptide 32
<p>S6 Kinase Substrate Peptide 32 is a peptide that measures the activity of kinases that phosphorylate ribosomal protein S6. It can also be used as a substrate.</p>Fórmula:C149H270N56O49Pureza:98%Cor e Forma:SolidPeso molecular:3630.1PROTAC MLKL Degrader-1
<p>PROTAC MLKL Degrader-1 (Compound 36) is a selective PROTAC degrader targeting MLKL, achieving a degradation maximum (D max) over 90%.</p>Fórmula:C46H55F2N9O9SCor e Forma:SolidPeso molecular:948.05BI1701963
<p>BI1701963 is an orally effective inhibitor that targets the SOS1 and KRAS interaction, specifically inhibiting the activation of KRAS by blocking its GTP loading. This compound is utilized in cancer research to explore potential therapeutic effects against KRAS-driven malignancies.</p>Fórmula:C47H62N8O4SCor e Forma:SolidPeso molecular:835.11(R)-BI-2852
CAS:<p>(R)-5-hydroxy isoindolin-1-one is an RAS protein inhibitor with antiproliferative and antitumor properties.</p>Fórmula:C31H28N6O2Pureza:97.78%Cor e Forma:SoildPeso molecular:516.59L-JNKI-1
L-JNKI-1 is a cell-permeable peptide inhibitor specific for JNK, it has been shown to effectively inhibit JNK activity in in vivo studies.Fórmula:C164H286N66O40Pureza:98%Cor e Forma:SolidPeso molecular:3822.44IPS-06061
<p>IPS-06061 is an orally active molecular glue that forms a ternary complex with CRBN and KRASG12D, capable of degrading KRAS G12D, with a DC50 of less than 500 nM.</p>Fórmula:C22H26O3Cor e Forma:SolidPeso molecular:338.44SIAIS562055
<p>SIAIS562055, a potent cereblon-based SOS1PROTAC, exhibits a dissociation constant (Kd) of 95.9 nM. It effectively degrades SOS1 and inhibits the downstream ERK pathway. SIAIS562055 disrupts the interaction between KRASG12C or KRASG12D and SOS1, with IC50 values of 95.7 nM and 134.5 nM, respectively. This compound demonstrates strong anticancer activity.</p>Fórmula:C49H62F3N7O5SCor e Forma:SolidPeso molecular:918.12PROTAC SOS1 degrader-4
<p>PROTAC SOS1 Degrader-4 (compound 10) is a potent degrader of SOS1 and exhibits antiproliferative activity [1].</p>Fórmula:C53H65ClN8O7SPureza:98%Cor e Forma:SolidPeso molecular:993.65KRAS G12D inhibitor 7
CAS:<p>KRAS G12D inhibitor 7, is a highly potent inhibitor specifically targeting KRAS G12D.</p>Fórmula:C32H38N8O3Cor e Forma:SolidPeso molecular:582.709YN14
<p>YN14 is a highly potent and selective KRASG12C proteolysis targeting chimera (PROTAC) capable of forming a stable KRASG12C: YN14: VHL ternary complex with low</p>Pureza:98%Cor e Forma:Odour SolidSS47
CAS:<p>SS47 is a PROTAC that degrades immunosuppressive HPK1 via proteasome; boosts BCMA CAR-T cell cancer therapy.</p>Fórmula:C49H56N6O12SCor e Forma:SolidPeso molecular:953.07KRAS G12D inhibitor 6
CAS:<p>KRAS G12D inhibitor 6 is an efficacious compound that effectively inhibits KRAS G12D.</p>Fórmula:C32H37ClN8O2Cor e Forma:SolidPeso molecular:601.15Ras Inhibitory Peptide acetate
<p>Ras Inhibitory Peptide acetate, involved in cancer-related Ras signaling.</p>Fórmula:C55H95N19O13Pureza:96.63%Cor e Forma:SolidPeso molecular:1230.464′-Demethylnobiletin
CAS:<p>4′-Demethylnobiletin, a bioactive metabolite, activates the PKA/ERK/CREB signaling pathway, enhances CRE-mediated transcription in hippocampal neurons, and</p>Fórmula:C20H20O8Cor e Forma:SolidPeso molecular:388.37PPM-3
<p>PPM-3, a selective PROTAC ERK5 degrader, exhibits a potent inhibitory concentration (IC 50) of 62.4 nM.</p>Fórmula:C54H69N11O6SPureza:98%Cor e Forma:SolidPeso molecular:1000.26Cobimetinib (R-enantiomer)
CAS:<p>Cobimetinib R-enantiomer is the less active R-enantiomer of Cobimetinib which is a selective MEK inhibitor.</p>Fórmula:C21H21F3IN3O2Pureza:98%Cor e Forma:SolidPeso molecular:531.318p38 MAP Kinase Inhibitor Ⅵ
CAS:<p>p38 MAP Kinase Inhibitor Ⅵ is a potent p38 MAP Kinase inhibitor with anti-inflammatory activity.</p>Fórmula:C16H13FN2OS2Pureza:98.53%Cor e Forma:SolidPeso molecular:332.42KRAS G12C inhibitor 69
<p>KRAS G12C inhibitor 69 (Compound K09) is an inhibitor of the mutant RAS protein KRAS G12C with an IC50 of 4.36 nM. In the cell lines NCI-H358 and MIA-PACA-2, it suppresses ERK phosphorylation with IC50 values of 12 nM and 7 nM, respectively. Additionally, KRAS G12C inhibitor 69 hinders the proliferation of NCI-H358 and MIA-PACA-2 cancer cells, with IC50 values of 3.15 nM and 2.33 nM, respectively.</p>Fórmula:C29H29ClF3N5O3Cor e Forma:SolidPeso molecular:588.02KRAS G12C inhibitor 60
<p>KRAS G12C Inhibitor 60 (compound 23), a selective inhibitor targeting the Kras-G12C mutation, is utilized in the investigation of lung, colorectal, and</p>Fórmula:C31H30F5N7O2Pureza:98%Cor e Forma:SolidPeso molecular:627.61Tagarafdeg
CAS:<p>Tagarafdeg (CFT1946) is a PROTAC degradator targeting mutant BRAF, capable of degrading BRAF V600E, G469A, G466V mutations, anti proliferation.</p>Fórmula:C45H49F2N11O9SPureza:＞99.99%Cor e Forma:SolidPeso molecular:958HPK1-IN-39
<p>HPK1-IN-39 (Compound 10n), a selective inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) with an inhibitory concentration (IC50) of 29 nM, impedes the</p>Fórmula:C26H27N7O2Cor e Forma:SolidPeso molecular:469.54Antimicrobial agent-21
CAS:<p>Antimicrobial agent-21 is a potent mitogen activated protein kinase inhibitor with antibacterial, anti-inflammatory and antitumor activity for the treatment of</p>Fórmula:C18H13N3OSPureza:99.82%Cor e Forma:SolidPeso molecular:319.38KRASG12C IN-14
<p>KRASG12C IN-14 (compound 15), a potent inhibitor specifically designed for the KRAS G12C mutation, exhibits impressive efficacy in impeding CYPA-dependent KRAS-BRAF interaction and ERK phosphorylation in NCI-H358 cells, both with an IC 50 of 0.002 μM.</p>Fórmula:C51H65F4N9O9S2Cor e Forma:SolidPeso molecular:1088.24Pan-RAS-IN-6
Pan-RAS-IN-6 (compound 24) serves as a DUSP6 inhibitor, effectively reducing MAPK activation in the NCI-H1373-Luc model (DUSP6). It concurrently exhibits notable tumor growth inhibition and regression in the NSCLC brain metastasis mouse model. The compound displays high selectivity and potent inhibitory effects, particularly on KRAS mutation-associated signaling pathways. It demonstrates varied inhibitory activities against distinct KRAS mutants and their interacting proteins. The IC 50 values for KRAS G12C, G12D, and G12V are 1.3 nM, 4.7 nM, and 0.3 nM, respectively.Fórmula:C46H60N8O5SCor e Forma:SolidPeso molecular:837.08BAS 00489700
CAS:<p>BAS 00489700 is a N-UTR interaction inhibitor. BAS 00489700 inhibits virus replication in cell culture.</p>Fórmula:C19H16N2O4Pureza:99.78%Cor e Forma:SolidPeso molecular:336.34HPK1-IN-20
CAS:<p>HPK1-IN-19 is a potent inhibitor of hematopoietic progenitor kinase 1 (HPK1).</p>Fórmula:C26H28N6O2Cor e Forma:SolidPeso molecular:456.55LYMTAC-2
<p>LYMTAC-2 is a lysosome-targeting chimera (LYMTAC) developed to degrade membrane-associated proteins through lysosomal membrane proteins (LMP) such as RNF152, LAPTM4a, and LAPTM5. It forms a ternary complex with target proteins like KRASG12D, facilitating their relocation to lysosomes and resulting in ubiquitin-dependent degradation. This compound has potential for studying membrane protein regulation and devising strategies to counter resistance in KRAS-driven signaling pathways.</p>Cor e Forma:SolidPeso molecular:1248.44Klotho-derived peptide 1 hydrochloride
<p>Klotho-derived peptide 1 (KP1 human) hydrochloride inhibits the interaction between TGF-β and TGF-β receptor 2, suppressing the activation of TGF-β-induced Smad2/3 and mitogen-activated protein kinase (MAPK). Additionally, it exhibits antifibrotic and renal protective effects in mouse models.</p>Cor e Forma:Odour SolidNUCC-0200808
<p>NUCC-0200808 (Compound 12g) is an MNK1 inhibitor with an IC50 of 42 nM. It reduces eIF4E phosphorylation and cell viability in AML cells and induces apoptosis. NUCC-0200808 shows potential for research in the field of leukemia.</p>Cor e Forma:Odour SolidMAP4K4-IN-6
<p>MAP4K4-IN-6 (Compound 15f) is a MAP4K4 inhibitor with an IC50 of 80 nM. It reduces the phosphorylation of c-Jun and exhibits neuroprotective effects. Additionally, MAP4K4-IN-6 enhances the vitality of motor neurons and can be utilized in the study of amyotrophic lateral sclerosis (ALS).</p>Cor e Forma:Odour SolidKRAS G12C inhibitor 18
CAS:<p>KRAS G12C inhibitor 18 is a potent, orally active compound that inhibits KRAS G12C and exhibits anti-tumor activities.</p>Fórmula:C25H20ClFN4O3SCor e Forma:SolidPeso molecular:510.97RTIL 13
CAS:<p>RTIL 13 inhibits dynamin GTPase (IC50: 2.3 μM), targets its lipid binding domain, and suppresses endocytosis (IC50: 9.3 & 7.1 μM).</p>Fórmula:C30H55BrN2O3Cor e Forma:SolidPeso molecular:571.685PROTAC MEK1 Degrader-1
CAS:<p>PROTAC MEK1 Degrader-1, a targeted protein degradation agent, combines a MEK1 inhibitor with a von Hippel-Lindau ligand to effectively inhibit ERK1/2</p>Fórmula:C53H66FIN8O11S2Pureza:98%Cor e Forma:SolidPeso molecular:1201.17KG5
CAS:<p>KG5 inhibits PDGFRβ, B-Raf, FLT3, KIT, c-Raf; has anticancer and antiangiogenic effects; Kd: 520 nM (PDGFRβ), 300 nM (PDGFRα).</p>Fórmula:C20H16F3N7OSPureza:98.32%Cor e Forma:SolidPeso molecular:459.45FAM49B (190-198) mouse
CAS:<p>FAM49B (190-198) mouse represents a peptide fragment of the mitochondria-localized protein FAM49B, which is instrumental in regulating mitochondrial fission, function, and integrity, in addition to influencing tumor progression. Beyond its role in mitochondrial dynamics, FAM49B serves as a negative regulator of T cell activation by inhibiting GTPase Rac activity and affecting cytoskeleton reorganization.</p>Fórmula:C49H71N9O14SCor e Forma:SolidPeso molecular:1042.2Setidegrasib
CAS:<p>KRAS G12D inhibitor 17, a quinazoline-linked prolinamide, degrades mutant KRAS protein; a PROTAC.</p>Fórmula:C60H65FN12O7SCor e Forma:SolidPeso molecular:1117.3DB-10
<p>DB-10 serves as a precursor to 3-nbutylphthalide (NBP). It is absorbed by cells in a temperature and energy-dependent manner through the pyrilamine cation transporter. DB-10 enhances cell survival and rapidly converts into an active form in vivo, increasing accumulation within the brain. This compound is applicable in ischemic stroke research.</p>Cor e Forma:Odour SolidGNE-9815
CAS:<p>GNE-9815 (3-(2-cyanopropan-2-yl)-N-[2-fluoro-4-methyl-5-(7-methyl-8-oxo-7,8-dihydropyrido[2,3-d]pyridazin-3-yl)phenyl]benzamide) is a high kinase-selective</p>Fórmula:C26H22FN5O2Pureza:99.08% - 99.1%Cor e Forma:SolidPeso molecular:455.48U0124
CAS:<p>Inactive analog of U0126(MEK-1/2 inhibitor), used as a negative control</p>Fórmula:C8H10N4S2Pureza:98%Cor e Forma:SolidPeso molecular:226.32
